April 12, 2021 @ 7:30am –
April 14, 2021 @ 11:15am
UTC+1
This Event has passed
€50 discount for YEAP members.
This is a standard WASP course with Faculty mostly comprised of internationally known cardiologists, cardiac surgeons, journal editors and more. All times in Programme are Malta (Rome) times.
The upcoming WASP course is being held in collaboration with HopeXchange, whose mission is the alleviation of suffering in developing countries through education, healthcare, and sustainable development.
There is now a Malta Cross Foundation partial (50%) scholarship for this course. The scholarship is open to all local and International students or young graduates. If interested send an email to info@maltacross.org copied to info@ithams.com. Subject: WASP Scholarship. For further information contact us on info@maltacross.org. The Foundation reserves the right to refuse any application.
Start:
End:
Cost:
April 12, 2021 @ 7:30 am UTC+0
April 14, 2021 @ 11:15 am UTC+0
€450
Start:
April 12, 2021 @ 7:30 am UTC+0
End:
April 14, 2021 @ 11:15 am UTC+0
Cost:
€450
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.